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Abstract 
Leptomeningeal metastasis (LM) is a terminal event in the development of non-small cell lung cancer (NSCLC). It has 
a poor prognosis with median survival of 1.9 months if untreated. The improvement of OS in NSCLC patients relatively 
increases incidence of LM. While current therapeutic options for LM are limited. Epidermal growth factor receptor-
tyrosine kinase inhibitors are a class of small molecules and show dramatic response in epidermal growth factor 
receptor mutated patients. It also has a distinct therapeutic potential against brain metastases. Although there are 
some studies on EGFR-TKIs and brain metastases, the role of EGFR-TKIs on LM are not fully clarified. In this review, we 
will summarize current evidences concerning the use and discuss the role of EGFR-TKIs on LM.
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Background
Lung cancer is the most common cancer and leading 
cause of cancer deaths in the world (Ferlay et al. 2010). As 
improvement in treatment for non-small-cell lung car-
cinoma (NSCLC), previous rare complications become 
evident. Leptomeningeal metastasis (LM), namely can-
cer cells spreading to the meninges, is a terminal event 
in the development of NSCLC (Chamberlain 2005). LM 
occurs in 5  % of cancers, and 14–29  % of them derives 
from lung cancer (Grossman and Krabak 1999). LM has 
a poor prognosis with median survival of 1.9  months if 
untreated (Herrlinger et  al. 2004). Intravenous chemo-
therapy is believed to have a limited role because its 
inability to form high drug concentrations in intrac-
ranial area due to blood brain barrier (BBB). Current 
available drugs for intrathecal chemotherapy (ITC) 
including methotrexate and cytarabine have limited 
antitumor activity in lung cancer (Oechsle et  al. 2010). 
Although whole brain radiotherapy (WBRT) is an effec-
tive therapy for brain parenchyma metastasis, it does 
not exhibit survival benefit on LM (Morris et  al. 2012). 
Epidermal growth factor receptor-tyrosine kinase inhibi-
tors (EGFR-TKIs) are a class of small molecules and 
have demonstrated dramatic response rates from 60 to 
90  % in sensitizing EGFR mutation NSCLC population 
as systemic therapy (Maemondo et  al. 2010; Mitsudomi 
et  al. 2010; Mok et  al. 2009). EGFR-TKIs also showed a 
distinct therapeutic potential against brain metastases of 
NSCLC (Namba et  al. 2004; Hotta et  al. 2004), suggest-
ing its ability to penetrate BBB into cerebrospinal fluid 
(CSF). In addition, EGFR-TKIs have antitumor efficacy 
in central nervous system metastases even for those 
patients with extracranial lesions failure after standard 
dose EGFR-TKIs treatment (Grommes et  al. 2011; Jack-
man et al. 2006; Dhruva and Socinski 2009; Clarke et al. 
2010; Kuiper and Smit 2013; Hata et al. 2011; Kawamura 
et  al. 2015). Notwithstanding there are some studies on 
EGFR-TKIs and brain metastases, the role of EGFR-TKIs 
on LM are not fully clarified. In this review, we will sum-
marize current evidences concerning the use and discuss 
the role of EGFR-TKIs on LM.
Definition and diagnosis of LM
LM is defined as the spread of malignant cells to the lep-
tomeninges and subarachnoid space and dissemination 
of tumors cells with the CSF compartment (Gleissner 
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and Chamberlain 2006). Symptoms of LM contains 
mental changes, headaches, seizures, and back pain, etc. 
However, it can also exhibit some abscopal symptoms. 
Sim et al. reported a case chest wall pain as the present-
ing symptom of LM (Sim et al. 2014). The gold standard 
of diagnosis with LM is detection of malignant cells in 
CSF (Chamberlain 2005). While CSF examination can 
only perform in part of patients. Therefore, the finding 
of meningeal enhancement in cranial and/or spinal MRI 
combine with neurological symptoms are also recognized 
as LM.
Current therapeutic modalities of EGFR‑TKIs for LM
EGFR-TKIs open up era of target therapy on NSCLC 
and markedly prolong OS and PFS on EGFRMT patients. 
The improvement of OS in NSCLC patients relatively 
increases incidence of LM. In the following part, we 
will focus on therapeutic options of EGFR-TKIs on LM. 
Table  1 summaries current clinical trials on application 
EGFR-TKIs for LM.
EGFR mutation versus wild type
EGFR mutation type (EGFRMT) NSCLC is an important 
subgroup of NSCLC, accounting for about 50 % in Asian 
and 10  % in Caucasian population (Hirsch and Bunn 
2009). Mounting evidences have shown EGFR-TKIs 
improved overall response rate (ORR), progression-free 
survival (PFS) and/or overall survival (OS) with mini-
mal toxicities in EGFR sensitive mutation patients (Mae-
mondo et  al. 2010; Mitsudomi et  al. 2010; Rosell et  al. 
2012; Sequist et  al. 2013; Zhou et  al. 2011). In the case 
of LM, EGFRMT type also contributed to longer OS and 
PFS as well as better performance status (PS). A retro-
spective study conducted by Umemura et al. showed the 
median survival time (MST) for all NSCLC patients with 
LM was 3.6 months, while MST in exon 19 deletion, exon 
21 mutation, and wild type patients were 11.0, 7.1, and 
1.4 months. Similar results were seen in PFS. The median 
time to progression (mTTP) for these three group were 
7.8, 2.0, and 0.9 months (Umemura et al. 2012). Although 
EGFR-TKIs have an initial good response, it inevita-
bly moves toward resistance around 1-year (Maemondo 
et al. 2010; Mitsudomi et al. 2010; Mok et al. 2009). Sev-
eral mechanisms lead to EGFR-TKIs resistance, includ-
ing secondary mutation (Primary T790M mutation), 
c-Met amplification, and transformation to small cell 
lung cancer (Kobayashi et  al. 2005). T790M mutation 
is an important mechanism of acquired resistance, and 
there are about 50  % T790M mutation in patients after 
TKI failure (Sequist et al. 2011; Oxnard et al. 2011; Chen 
et al. 2009; Balak et al. 2006). Most of LM occurs at late 
course of NSCLC, patients usually have acquire resist-
ance of EGFR-TKIs. However, intracranial metastases 
retain sensitive mutation even when extracranial lesions 
develop secondary mutation such as T790M (Jackman 
et  al. 2006; Clarke et  al. 2010; Balak et  al. 2006; Heon 
et al. 2010). Lack of selection pressure as poor penetra-
tion of TKIs in intracranial metastases might explain this 
phenomenon.
First, second, and third‑generation EGFR‑TKIs
As first-generation EGFR-TKIs, erlotinib (Tarceva) and 
gefitinib (Iressa) exhibit dramatic efficacy in selected 
NSCLC patients. Each of them has evidence prov-
ing their efficacy as first-line, second-line, third-line, or 
maintenance therapy (Mok et  al. 2009; Qi et  al. 2012; 
Alimujiang et  al. 2013). Certainly, there are some stud-
ies comparing efficacy and toxicity between erlotinib 
and gefitinib. Burotto et al. found both of them had simi-
lar toxicity profiles as well as outcomes including ORR, 
PFS, and OS (Burotto et  al. 2015). However, Wu et  al. 
conducted a study enrolled 716 patients, and found dif-
ferent effectiveness between gefitinib and erlotinib for 
NSCLCMT patients (Wu et  al. 2011). In addition, sev-
eral studies showed erlotinib produced clinical benefits 
in some patients after gefitinib failure (Hata et  al. 2011; 
Kaira et al. 2010). Similar phenomenon was seen in LM. 
Several studies reported erlotinib had a good response 
for LM after gefitinib failure (Yang et al. 2015; Yuan et al. 
2012; Masuda et al. 2011; Katayama et al. 2009). Erlotinib 
was believed to have more penetration rate into the CSF 
than gefitinib. Togashi et  al. compared CSF concentra-
tion and penetration rate between gefitinib and erlotinib 
in 15 patients (Togashi et  al. 2012). The results showed 
the CSF concentration for gefitinib and erlotinib were 
8.2  ±  4.3  nM and 66.9  ±  39.0  nM, respectively. The 
penetration rate were 1.13  ±  0.36 and 2.77  ±  0.45  %, 
respectively. Patients with erlotinib also achieved a pref-
erentially higher intracranial response rate than those 
with gefitinib (4/7 vs. 1/3). Another study retrospectively 
analyzed the two EGFR-TKIs efficacy on 25 NSCLC 
patients with LM (Lee et  al. 2013). They found patients 
with erlotinib showed better cytological conversion rate 
of LM than those with gefitinib (9/14 vs. 1/11). In addi-
tion, another first-generation EGFR-TKI icotinib also 
showed efficacy on LM from NSCLC with EGFR muta-
tion (Gong et  al. 2015). Of course, second-generation 
(Afatinib) and third-generation TKIs (AZD9291) have 
been applied in clinical practice or clinical trials. Lux-
Lung 3 and Lux-Lung 6 showed first-line afatinib sig-
nificantly prolonged PFS compared to platinum-based 
chemotherapy (Sequist et  al. 2013; Wu et  al. 2014). 
Pooled analysis of Lux-Lung 3 and Lux-Lung 6 showed 
afatinib improved OS in patients with del19 EGFR muta-
tions but not Leu858Arg EGFR mutations, indicating 
the potential mechanistic differences between afatinib 
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and first-generation EGFR-TKIs (Yang et  al. 2015). 
Recent two studies Lux-Lung 7 and Lux-Lung 8 com-
pared afatinib with gefitinib and erlotinib showing supe-
riority of afatinib in PFS and OS (Park et al. 2016; Soria 
et al. 2015). Lin et al. reported a case afatinib combina-
tion with cetuximab was effective for LM after erlotinib/
gefitinib failure (Lin et al. 2014). Another report on out-
comes of pretreated NSCLC patients with CNS metasta-
sis who received afatinib showed that thirty-five percent 
(11 of 31) of evaluable patients had a cerebral response 
(Hoffknecht et  al. 2015). CSF data from one patient 
showed afatinib CSF concentration of approximately 
1.0 nM. Afatinib appears to penetrate into the CNS with 
concentrations high enough to have clinical effect on 
CNS metastases. Osimertinib (AZD9291) is a third-gen-
eration EGFR-TKI. BLOOM study showed osimertinib 
demonstrated encouraging preliminary activity in heav-
ily pretreated patients with LM disease from EGFRMT 
NSCLC (Yang 2016). Ahn et  al. analyzed patients with 
brain metastasis from AURA and AURA2 studies and 
showed osimertinib achieved an ORR of 56 % (Ahn et al. 
2015). CSF data from one patient showed AZD9291 CSF 
concentration of 3.44  nM. Nanjo et  al. established an 
in vivo LM mice model and found osimertinib markedly 
inhibited progression of LM even after refractory to erlo-
tinib (Nanjo et al. 2016).
High‑dose versus standard dose EGFR‑TKIs
Traditional chemotherapy is unable to penetrate into 
CSF due to BBB. This causes limited efficacy of sys-
temic therapy on intracranial lesions. EGFR-TKIs are a 
class of small molecular agents and supposed to easily 
penetrate into the CSF, however, the penetration rate is 
still low. Therefore, intracranial failure of EGFR-TKIs is 
consider as pharmacokinetic failure. Higher dose EGFR-
TKIs is supposed to correlate with higher concentra-
tions in the CSF. Togashi et  al. studied the relationship 
between plasma and CSF concentrations of erlotinib 
(Togashi et al. 2011). The authors found the plasma erlo-
tinib concentrations at a dose of 75 and 150  mg were 
433 and 1117 nM, corresponding to CSF concentrations 
14 and 44  nM. There was a good correlation between 
plasma and CSF concentrations (R2  =  0.84, p  <  0.001). 
For that matter, a series studies have evaluated the effi-
cacy of high-dose EGFR-TKIs on intracranial metastases 
from NSCLC. Kawamura et  al. analyzed safety and effi-
cacy of 35 patients with or without high-dose erlotinib 
and found high-dose erlotinib significantly improved 
PS and neurological symptoms with no elevated rates of 
severe adverse events (AEs) as compared to standard-
dose EGFR-TKIs (Kawamura et al. 2015). Median OS in 
high-dose erlotinib and standard-dose EGFR-TKIs were 
6.2 and 5.9 months, respectively (Kawamura et al. 2015). 
Jackman et  al. conducted a phase I study of high-dose 
gefitinib on LM from NSCLC and found high-dose gefi-
tinib could improve neurological symptoms with minor 
toxicity (Jackman et  al. 2015). Several studies reported 
high-dose EGFR-TKIs improved neurological symptoms 
and decreased intracranial metastases after standard-
dose EGFR-TKIs failure (Dhruva and Socinski 2009; 
Clarke et al. 2010; Kuiper and Smit 2013; Hata et al. 2011; 
Yuan et al. 2012).
Combination with WBRT
WBRT has an important role in brain metastases, while 
its impact on LM is unknown. A study of Morris et  al. 
showed WBRT might play a role in symptom control, 
but it did not improve OS of LM patients (Morris et al. 
2012). Although WBRT alone does not exhibit superior 
outcomes, combination with EGFR-TKIs seems to be 
effective. In Yang’s study, four patients achieve partial or 
complete response who received WBRT, while the other 
two patients achieve stable disease who did not combine 
with WBRT (Yang et  al. 2015). Of course, the sample 
size is small, further study are needed to evaluate WBRT 
combination with EGFR-TKIs.
Conclusion
LM is a terminal event of NSCLC and its prognosis is 
extremely poor. Current therapeutic options for LM are 
limited. EGFR-TKIs as important target drugs exhibit 
good efficacy for EGFRMT patients with LM. In this 
review, we discuss selection and therapeutic strategy of 
EGFR-TKIs for LM. EGFRMT patients with LM might 
be more appropriate for EGFR-TKIs therapy than those 
EGFR wild type patients. It seems erlotinib and high-
dose regimen could benefit more patients. Also combina-
tion with WBRT is another option. Nevertheless, current 
evidence are derived from respective and case reports 
study, further randomized control trials are needed to 
fully understand the role of EGFR-TKIs for LM.
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